Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma

Figure 8

The role of the tumor DNA methylation score (DMS) in the prediction of immunotherapeutic benefits. (a–d) In the high DMS group, the IPS scores of the four types were significantly higher than those in the low DMS group. (e, f) The high DMS group was more likely to benefit from immunotherapy in the imvigor210 cohort. (g) The high DMS group lived significantly longer than the low DMS group. (h, i) In GSE78220, the objective response rate to anti-PD-L1 treatment in the high DMS group was higher than that in the low DMS group. (j) The patients with high DMS had better survival in the GSE78220 data.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)